<DOC>
	<DOCNO>NCT02878889</DOCNO>
	<brief_summary>A Phase II Trial S-1 Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma .</brief_summary>
	<brief_title>A Phase II Trial S-1 Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>proven locoregional recurrence curative treatment unsuitability local treatment , distant metastasis presentation acquire metastasis curative treatment . presence least one measurable disease , define lesion could measure least 20 mm one dimension conventional compute tomography ( CT ) least 10 mm spiral CT scan ; KPSâ‰¥70 , life expectancy least 6 month . malignancy prior study entry ; boneonly metastasis ; previous radiotherapy within 4 week ; previous exposure gemcitabine ; patient active , noncontrolled infection severe systemic disease , congestive heart failure , angina pectoris , respiratory insufficiency arrhythmia reject enrollment . Other exclusion criterion include concurrent treatment investigational drug , hypersensitivity platinum compound , current pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>